Inotiv, Inc. (NOTV)
- Previous Close
1.9200 - Open
1.9300 - Bid 1.8300 x 300
- Ask 1.9100 x 900
- Day's Range
1.7800 - 1.9300 - 52 Week Range
1.1500 - 6.4800 - Volume
287,616 - Avg. Volume
813,223 - Market Cap (intraday)
65.029M - Beta (5Y Monthly) 3.98
- PE Ratio (TTM)
-- - EPS (TTM)
-4.6100 - Earnings Date May 7, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.50
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. It operates through two segments, Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DMS segment manufactures scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.
www.inotiv.com1,977
Full Time Employees
September 30
Fiscal Year Ends
Sector
Industry
Recent News: NOTV
View MorePerformance Overview: NOTV
Trailing total returns as of 4/25/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NOTV
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NOTV
View MoreValuation Measures
Market Cap
63.34M
Enterprise Value
472.40M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.10
Price/Book (mrq)
0.37
Enterprise Value/Revenue
0.99
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-25.40%
Return on Assets (ttm)
-4.78%
Return on Equity (ttm)
-56.93%
Revenue (ttm)
475.11M
Net Income Avi to Common (ttm)
-120.69M
Diluted EPS (ttm)
-4.6100
Balance Sheet and Cash Flow
Total Cash (mrq)
38.04M
Total Debt/Equity (mrq)
263.27%
Levered Free Cash Flow (ttm)
19.3M